fig6

Figure 6. Cell survival rates of primary-like upcyte hepatocytes treated for 72 h with atazanavir (ata) alone (A), and for 653-03 (B), HC10-45 B3 (C), and HepaFH3 (D) cells treated with SN-38 alone and in combination with atazanavir. Cell viability was assessed using the CellTiter-Glo® 2.0 Cell Viability Assay. Calculated IC₅₀ were statistically compared using a two-tailed unpaired t-test with three biological replicates. Significance levels are denoted as follows: ^**P < 0.01 and ^***P < 0.001.